The unique mechanism of action of DaliRasen, how to accurately target the treatment?

Daridorexant is a new type of insomnia treatment drug. Its unique mechanism of action gives it obvious advantages in precise targeted treatment of insomnia. Different from traditional sedative-hypnotic drugs, Dalitrazolin is a dual orexin receptor antagonist (DORA), which regulates the sleep-wake cycle by blocking the orexin (Orexin) signaling pathway, thus achieving the effect of promoting sleep. Its precise targeting mechanism not only improves sleep quality, but also reduces common adverse reactions of traditional sleeping pills, such as daytime sleepiness, addiction and impaired cognitive function.

The targets of DaliRazen are orexin receptor 1 (OX1R) and orexin receptor 2 (OX2R). These receptors are located in the hypothalamus area of the brain and are responsible for regulating arousal state. Orexin (also known as hypocretin) is a neuropeptide that plays a key role in maintaining a state of wakefulness and alertness. Normally, the orexin system is active during the day, helping the brain stay awake, while at night, orexin activity decreases, helping to fall asleep. However, in people with insomnia, the orexin system may be overactive, making it difficult to fall asleep or stay asleep. By blocking OX1R and OX2R receptors, DaliRasen inhibits the wake signal of orexin, making it easier for the brain to enter sleep state and maintain deep sleep for a longer period of time.

Compared with traditionalGABA (gamma-aminobutyric acid) sedative-hypnotic drugs such as benzodiazepines (such as diazepam, alprazolam) or Z drugs (such as zopiclone, zolpidem), the effect of dalirasin is more targeted. Traditional sleeping pills mainly reduce the overall neural activity by enhancing the inhibitory effect of the GABA pathway to achieve a sedative and hypnotic effect. However, this widespread depression of the central nervous system often leads to side effects such as dependence, increased tolerance, residual effects in the morning (e.g., drowsiness, dizziness), and impairment of cognitive function. In contrast, DaliRazen avoids the inhibitory effect on the entire nervous system by selectively inhibiting the orexin pathway, so it has fewer side effects, especially less impact on daytime alertness.

The advantages of DaliRasen in precise targeted treatment of insomnia are also reflected in its pharmacokinetic properties. Its half-life is about 6-8 hours, which is enough to maintain a full night's sleep without causing drowsiness the next morning. This is in sharp contrast to the half-life of traditional long-acting sedative-hypnotic drugs (such as flurazepam and clonazepam), which often exceeds 12 hours. The metabolism of dalirasin in the human body is mainly carried out through the CYP3A4 enzyme system, and the metabolites are relatively inactive. Therefore, its drug accumulation effect is low, and long-term use will not lead to a decrease in drug efficacy or an increase in dependence. In addition, clinical studies have shown that DaliRasen has significant effects in improving the time it takes to fall asleep, prolonging total sleep time and improving sleep quality without causing damage to memory or attention the next day, which is particularly important for patients who need to maintain high cognitive function during the day.

Another advantage is the protective effect of DaliRazen on physiological sleep structures. Traditional sleeping pills tend to inhibit REM (rapid eye movement) sleep, leading to fewer dreams in patients and may even affect mood regulation and memory consolidation. DaliRasen does not significantly affect REM sleep, but adjusts the sleep-wake balance to bring the patient's sleep structure closer to the natural state. Therefore, patients can not only get longer sleep time after using DaliRasen, but also maintain higher sleep quality and avoid cognitive and emotional problems caused by REM sleep deprivation.

Reference materials:https://www.quviviq.com/